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Background:  Functional domains of pro-EMAP II 
play an important role in Multi-Aminoacyl tRNA 
Synthetase (MSC) Complexes. 
Results: Pro-EMAP II’s N-terminus binds to its C-
terminus, arginyl-tRNA synthetase and neurofilament 
light subunit, and contains a putative leucine-zipper. 
Conclusion: N-terminus of pro-EMAP II facilitates 
its interaction with MSC complexes. 
Significance:  Understanding these binding domains 
may provide important insight into transcriptional 
regulation. 
 
ABSTRACT 
Pro-EMAP II, one component of the Multi-
Aminoacyl tRNA Synthetase (MSC) Complex, 
plays multiple roles in physiological and 
pathological processes of protein translation, 
signal transduction, immunity, lung development 
and tumor growth. Recent studies determined that 
pro-EMAP II has an essential role in maintaining 
axon integrity in central and peripheral neural 
systems where deletion of pro-EMAP II’s C-
terminus was reported in a consanguineous Israeli 
Bedouin kindred suffering from Pelizaeus-
Merzbacher-like disease. We hypothesized that 
pro-EMAP II’s N-terminus had an important role 
in the regulation of protein-protein interactions. 
Using a GFP reporter system, we defined a 
putative leucine-zipper in the N-terminus of 
human pro-EMAP II protein (amino acid residues 
1-70), which can form specific strip-like punctate 
structures. Through GFP punctate analysis, we 
uncovered that pro-EMAP II’s C-terminus (147-
312 amino acid residues) can repress the GFP 
punctate formation. Pull-down assays confirmed 
the binding between pro-EMAP II N-terminus 
and its C-terminus is mediated by a putative 
leucine-zipper. Furthermore, the pro-EMAP II 1-
70 aa region was identified as the binding partner 
of the arginyl-tRNA synthetase (RARS), a 
polypeptide of MSC complex. We also determined 
that the punctate GFP pro-EMAP II 1-70aa 
aggregate co-localizes and binds to the 
neurofilament light (NFL) subunit protein that is 
associated with pathologic neurofilament network 
disorganization and degeneration of motor 
neurons. These findings indicate the structure and 
binding interaction of Pro-EMAP II protein and 
suggest a role of this protein in the pathological 
neurodegenerative diseases.     
___________________________________________ 
Endothelial Monocyte-Activating Peptide II (EMAP 
II) was initially isolated and identified as a 22kD pro-
inflammatory cytokine secreted from a murine 
methylcholanthrene A-induced fibrosarcoma (1-4). 
Later studies confirmed that EMAP II was the C-
terminus (147-312aa) of pro-EMAP II cleaved under 
apoptosis and by protease inhibitors (5-7). Pro-
EMAP II, also known as p43, AIMP1 and Scye I, 
encodes one component of Multi-Aminoacyl tRNA 
Synthetase Complex (MSC) and is involved in 
protein translation. Mechanistically, the C-terminus 
of EMAP II has been determined to induce apoptosis 
in endothelial cells, inhibit angiogenesis and tumor 
growth through inhibition of vascular endothelial 
growth factor (VEGF) mediated signaling and 
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alpha5beta1 integrin mediated deposition of the 
extracellular matrix  protein fibronectin (8-10). 
Expression and secretion of EMAP II is relevant to 
prognosis of some cancer patients and found to be 
involved in diverse biological process such as lung 
development, immune responses and glucose 
metabolism in pancreas (11-15). These imply the 
importance of EMAP II in the diagnosis and 
treatment of cancer and other diseases (16-20).  
 
Intracellularly, pro-EMAP II directly interacts with 
other components of MSC such as p38, arginyl-tRNA 
synthetase (RARS) and glutaminyl-tRNA synthetase 
(QARS) (21-24). Such interaction plays an important 
role in the assembly and function of MSC. In 
addition, through C-terminus binding with E3 
ubiquitin ligase Smurf2, pro-EMAP II stabilizes 
Smurf2 and down regulates the TGF-beta signaling 
pathway (25). Additional studies unveiled functional 
mechanisms and domains of pro-EMAP II protein 
(26,27). Park SG et al identified pro-EMAP II ’s N-
terminus 4-46aa region to be important in promoting 
fibroblast cell proliferation and wound repair (28). 
Pro-EMAP II was also determined to bind with heat 
shock protein HSP90B1/gp96, which plays critical 
role in innate and adaptive immunity (16,29). Based 
on sequence analysis, Guo M et al (2010) (30) 
introduced a novel concept that during evolution, the 
N-terminus of pro-EMAP II was preserved due to 
evolutionary pressure and the C-terminus gained 
cytokine functions through the accumulation of 
mutations and this may be the reason for the diverse 
functions of EMAP II.  
 
Recently studies have determined some biological 
roles for pro-EMAP II. Zhu X et al (2009) (31) found 
that pro-EMAP II directly interacts with 
neurofilament light (NFL) chain and down-regulates 
neurofilament phosphorylation. Depletion of pro-
EMAP II resulted in neurofilament network 
disorganization and degeneration of motor neurons. 
In 2010, pro-EMAP II truncation at the C-terminus 
was identified in consanguineous Israeli Bedouin 
kindred who suffered from Pelizaeus-Merzbacher-
like disease (PMLD) (32,33) (34), indicating the 
requirement of further evaluation of the structure and 
functionality of pro-EMAP II in different biological 
processes. The role of pro-EMAP II in MSC, 
regulation of gene expression and modification, the 
interaction with other proteins and the functionality 
in different cell types requires further and detailed 
exploration. Here we established an approach to 
study the structure and function of pro-EMAP II 
using GFP punctate analysis and pull-down assay. 
We found that the N-terminus of pro-EMAP II can 
form specific strip like punctate structure. We 
characterized this structure as a putative leucine-
zipper of pro-EMAP II. We also determined that the 
C-terminus of pro-EMAP II could bind with its N-
terminus to repress punctate structure formation, and 
co-localizes to the neurofilament light subunit 
protein. Furthermore, our studies indicate that the 1-
70aa region in the N-terminus of pro-EMAP II is 
responsible for its binding to the MSC subunits. 
 
EXPERIMENTAL PROCEDURES 
 
Cells, reagents and antibodies: 
Human lung adenocarcinoma A549, Human 
Embryonic Kidney 293 and human neuroblastoma 
SH-SY5Y cells utilized in studies for neuronal 
function and differentiation. Cells were maintained in 
DMEM containing 10% fetal bovine serum and 5 
mg/ml L-glutamine at 37◦C in 10% CO2. Human fetal 
kidney HEK293 cells were maintained in DMEM 
containing 5% fetal bovine serum at 37◦C in 5% CO2.  
GeneExpressoTM 8000 In Vitro DNA 
Transfection Reagent was purchased from InnoVita 
Incoporation, Gaithersburg, MD; Lipofectamine 2000 
and Hoechst 33342 from Invitrogen, Carlsbad, CA; 
TransIT LT 1 from Mirus Bio, LLC, Madison, WI, 
PS-341 from Millenium Pharmaceuticals, 
Cambridge, MA; Bredfeldin A, B-1080 Bafilomycin 
A1 (Baf A1) and Chloroquine were from Sigma-
Aldrich St. Louis, MO and Bio-Rad Protein Assay 
Dye Reagent Concentrate was from Bio-Rad 
Laboratories, Inc., Hercules, CA. Disuccinyl suberate 
(DSS) was purchased from Thermo Fisher 
Scientific Rockford, IL and BL21 DE3 strain was 
purchased from Stratagene (Cat.230255). Antibodies 
against GFP were purchased from Invitrogen 
(cat#A11122) and Santa Cruz Biotecnologies (Santa 
Cruz, CA) (cat#sc-9996).  Antibody against EMAP II 
was raised from rabbit in our lab (ref). Antibodies 
against GM130 (sc-55590) and GST (sc-33613) were 
purchased from Santa Cruz. 
 
PCR cloning and detection: 
For cloning, PCR reactions were carried out using 
high fidelity DNA amplification kit (Sigma-Aldrich) 
containing 10 pmol of each primer and 10 ng of DNA 
template. For RT-PCR and real-time PCR, total RNA 
was isolated from cells using Trizol reagent. Reverse 
Transcription was carried out using Superscipt III 
RT-PCR System according to manufacture’s 
instruction (Invitrogen Corp). Oligonucleotides were 
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synthesized by Invitrogen and Sigma-Aldrich. N-
terminus 1-102aa of RARS gene was amplified using 
oligos 5’- 
AACGAATTCAACCATGGACGTACTGGTGTCT
GAGT-3’ and   5’-
CTTGTCGACCACTAGCAGAGGAGGATTTTCC
A-3’.  N-terminus 1-108aa of human QARS gene was 
amplified using oligos 5’-
AACGAATTCAACCATGGCGGCTCTAGACTCC
CTGT-3’ and  
5’-
CTTGTCGACCTCGAAGTCCACAGTGTCGAT-
3’.  
 
Plasmid Construction:  
The EMAP II plasmid was used as a template for 
amplification of N-terminus, C-terminus and 
truncation of human pro-EMAP II using 
oligonucleotides (Supplemental Table 1). PCR 
fragments were digested and cloned into vector 
pEGFP-N3 for overexpression of GFP fusion protein. 
Site-directed mutation was performed using 
overlapped oligonucleotides for PCR. In brief, N-
terminus and C-terminus fragments containing 
mutations were amplified respectively. The PCR 
fragments were combined and used for PCR 
template. Site-directed mutated fragments were 
inserted into pEGFP-N3 vector. PCR cloned 
fragments were also cloned into vector pET28a(+) 
and pGEX-4T-3 for overexpression of His- or GST-
tagged protein in E. coli. DNA sequencing and/or 
restriction digestion analysis was used to confirm 
plasmid sequence. Reporter plasmid EYFP-GalT, 
Lamp1-YFP, pEGFP-C1-wtVHL, EGFP-supervillin 
and DsRed-rab7 WT were purchased from Addgene 
(Cambridge, MA). 
 
Transfection and stable clones: 
Cells were seeded in 24-well plates or in chamber 
slides 24 hours prior to transfection. A549 cells were 
transfected using reagent TransIT LT1 or 
GeneExpressoTM 8000. HEK-293 cells were 
transfected using Lipofectamine 2000 according to 
manufacture’s protocol. Analysis for GFP punctate 
formation was performed on live cells. Cells were 
observed and photographed after 20 hours under 
fluorescence microscopy. 100-200 GFP positive cells 
were analyzed per experiment and these were 
confirmed with using 3-6 replicates from independent 
experiments performed on different occasions. For 
drug treatment experiments, final concentration of 5 
mg/ml BFA, 50 nM Baf A1, 1 mM DTT, 10 nM PS-
341, 50 mM chloroquin or PBS was applied to cells 1 
hour after transfection. For immunofluorescence 
analysis, cells were treated with 10 mg/ml of BFA or 
PBS for 4h, or treated with 10 nM of PS-341 or PBS 
for 8h prior to further analysis. For stable clones of 
A549 or SH-SY5Y, cells were selected in complete 
medium containing 800 µg/ml or 600 µg/ml of G418 
for 2 weeks. Single colonies were picked up for 
expanding cultures. Expression of GFP-fusion 
protein was confirmed using fluorescence 
microscopy and Western blotting analysis. 
 
Cross-linking using DSS: 
Transfected cells were harvested and washed three 
times with PBS. Cells were then suspended in PBS at 
1 X 107 cells/ml and incubated with 1 mM DSS for 
20 min. Reactions were quenched by adding Tris-
HCl buffer (pH 7.5) to a concentration of 20 mM and 
incubated for 15 min. Cells were then pelleted, 
rinsed, suspended in 1 X SDS loading buffer, and 
sonicated to disrupt sticky genomic DNA prior to 
being subjected to SDS-PAGE analysis. 
 
Immunofluorescence: 
Cells were rinsed with PBS, fixed in 4% 
paraformaldehyde, and permeabilized with 0.2% 
Triton X-100. After blocking in CAS solution, cells 
were incubated with the specific primary antibody, 
followed by specific secondary FITC or Cy-3 
conjugated secondary antibodies. Cells were washed 
with PBS for 4 times and mounted with SlowFade 
Gold Antifade Reagent with DAPI  (Invitrogen). 
Fluorescent Microscope was used for imaging 
analysis.  
 
Immunoblot analysis: 
Cells were lysed at 4◦C in RIPA buffer or 1 X lysis 
buffer (50 mM Tris-Cl, pH 7.4, 10 mM MgCl2, 100 
mM NaCl, 1% Triton X-100, 10% glycerol, 1 mM 
DTT, and 1X protease inhibitor cocktail). Lysate was 
cleared by centrifugation at 4◦C at 13,200rpm for 20 
minutes. The protein concentration was measured 
using BioRad Protein Assay reagents according to 
manufacture’s manual. Equal amounts of protein 
were subjected to SDS-polyacrylamide gel and 
blotted to PVDF membrane. The blots were blocked 
in 5% non-fat milk, incubated with primary antibody, 
followed by the appropriate secondary antibody. 
Specific signals were measured using a detection kit 
from Amersham Biosciences. 
 
Pull-down assay: 
Pull-down assays were performed using ProFoundTM 
Pull-Down PolyHis Protein:Protein Interaction Kit 
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(Pierce). Briefly, BL21 DE3 competent E. coli were 
transformed with plasmids constructed in vector 
pET28a(+) and pGEX-4T-3 and fusion proteins were 
induced with 2 µg/ml IPTG. Following rinsing with 
TBS at 4°C, pellets were suspended in Profound lysis 
buffer and incubated for 30 min on ice. The crude E. 
coli lysate was clarified through 12,000xg 
centrifugation, the supernatant was collected and 
used as bait or prey protein for pull-down assay. 
When PolyHis-tagged proteins were used as bait 
protein, 40 mM final concentration of Imidazole was 
used in binding and washing buffers and proteins 
were eluted with buffer containing 290 mM of 
Imidazole. 
 
Flow cytometry sorting and mass spectrometry: 
SH-SY5Y stable clone cells overexpressing 1-70aa of 
pro-EMAPII fused with GFP were trypsinized for 
harvesting. After washing with PBS, cells were 
suspended in lysis buffer containing 1% Triton X-100 
and rotated at 4°C for 30 min, followed by 
centrifugation at 1,000 rpm for 10 min. Pellets were 
suspended in lysis buffer and washed again. Pellets 
were then re-suspended in lysis buffer and sonicated. 
Supernatant was transferred to new tubes after 
centrifugation at 1,500 rpm for 10 min and sorted by 
flow cytometry as previously described (35). 
Enrichment of GFP punctates were confirmed under 
microscopic observation. GFP punctates were 
pelleted down after centrifugation at 5,000 rpm for 10 
min. Pellet was suspended in 1X SDS loading buffer, 
boiled, and subjected to 12 % SDS-PAGE and run 
into separation gel about 1 cm. The gel was stained 
and destained according to Coomassie blue staining 
protocol. The gel was cut out and analyzed by mass 
spectrometry. 
 
Statistical Analysis:  
Prism software was used to perform all statistical 
analyses. All results are expressed as mean + SEM.  
The significance of differences between two sample 
means was determined by unpaired two-tailed 
Student’s t tests using 95% confidence intervals.  A p 
value less than 0.05 were considered significant. 
Water solubility was determined using software at 
http://www.innovagen.se/custom-peptide-
synthesis/peptide-property-calculator/peptide-
property-calculator.asp. Coiled-coil structures were 
identified using Lupas software at 
http://www.ch.embnet.org/software/COILS_form.ht
ml. 
 
  
RESULTS 
Overexpression of truncated isoforms of the pro-
EMAP II protein uncovered an N-terminus 1-70aa 
region responsible for the aggregation of EMAP II 
punctate formation  
 
Although much is known regarding the activities and 
functions of mature C-terminus EMAP II, little is 
understood about the functions of its intracellular 
precursor form pro-EMAP II protein. A549 cells 
overexpressing the full-length pro-EMAP II (1-
312aa) fused with GFP were noted to have dotted-
like GFP punctate structure in <1% of GFP-positive 
cells (Figure 1B). Multiple truncations of the C and N 
terminus regions of EMAP II were utilized to identify 
the region of pro-EMAP II responsible for the 
punctate formation. We determined that the 1-70 
amino acid region in the N-terminus promoted the 
GFP punctate formation as 45.2% of GFP positive 
cells contained GFP punctate formation (p<0.01 
compared to full-length pro-EMAP II, Figure 1D, 1J) 
as compared to 0% GFP punctate formation in 
truncated 99-312aa (Figure 1I, 1J) and 13% GFP 
punctate lesions in pro-EMAP II 1-192aa (Figure 1C, 
1J). Furthermore, truncation of the pro-EMAP II 
protein to 1-60aa abolished the GFP punctate 
formation (Figure 1E, 1J). When 21aa (22-70aa) 
(Figure 1F, 1J), 38aa (39-70aa) (Figure 1G, 1J) or 
58aa (59-70aa) (Figure 1H, 1J) of the N-terminus of 
pro-EMAP II were truncated, GFP punctate ratio 
dramatically decreased (p<0.01 comparing to 1-70aa 
truncation). These results suggested that the entire 1-
70aa region of pro-EMAP II is essential for GFP 
punctate formation.  
In addition to the quantitative amount of GFP 
punctation, profound morphological change of GFP 
punctate was also observed in transfection with 1-
70aa truncations. In transfection with full-length pro-
EMAP II, GFP punctate was dotted-like in structure 
and peri-nuclei as shown in the left panel of Figure 
1K. In contrast, the pro-EMAP II 1-70aa truncation 
expressed marked variation of punctate formation 
that was much stronger and strip-like shaped as 
shown in Figure 1L-S, however no branches in the 
strip-like GFP punctate pattern were observed. 
Similar results were observed in transfection of 
HEK293 (Figure 2A-C, G) and SH-SY5Y 
neuroblastoma cells (Figure 2D-G) using different 
transfection reagent such as Lipofectamine 2000, 
TransIT LT1, Fugene 6, GeneExpressoTM 8000 (data 
not shown). No punctate lesions were noted in the C-
terminus EMAP II 147-312aa cells (data not shown). 
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Analysis of GFP-punctate formation uncovered the 
role of leucine-like residues in 1-70aa region of pro-
EMAP II. 
Across species, the 1-70aa region of pro-EMAP II 
(AIMP1) is highly conserved during evolution 
(Figure 3A), implying the importance of N-terminus 
of pro-EMAP II. To investigate the function of the 
putative acetylation sites of pro-EMAP II’s 1-70aa 
region, ten lysine residues were identified and stripe-
replacement was performed to replace lysine residues 
with alanine residues found between amino acid 8 to 
11 (Figure 4D) and 46 to 63 (Figure 4C). 
Transfection analysis showed no significant 
difference in GFP punctate formation between 
alanine replacements (Figure 4C and 4D) and wild 
type (Figure 4B) (Figure 4Q).  
We next turned our attention to the hydrophobic 
amino acids leucine and isoleucine residues within 
this region that have frequently been identified in 
protein–protein interactions and binding recognition 
sites for hydrophobic ligands respectively. Site-
directed replacement of leucine or isoleucine residues 
with alanine residue at amino acid I21→A, L25→A, 
L31→A, L32→A, I37→A, L38→A, L42→A, 
L55→A, I59→A, and  L62→A abolished GFP 
punctate formation (Figure 4E,G-O,Q). However, 
while replacement of isoleucine residues with an 
alanine residue at amino acid I22→A showed no 
significant difference (Figure 4F), exchange of a 
leucine for an alanine at amino acid L66→A showed 
a significant decrease in GFP punctate formation 
comparing with wild type (Figure 4P,Q). These 
results suggested leucine and isoleucine residues are 
important in the GFP punctate formation of 1-70aa 
pro-EMAP II.  
 
Regions within the C-terminus of pro-EMAP II were 
determined to induce repression of the GFP punctate 
formation and induce morphologic GFP punctate 
alterations. 
Overexpression of full-length pro-EMAP II markedly 
decreased the GFP punctate formation as compared 
with the 1-70aa isoform. To define the region within 
the pro-EMAP II protein that repressed its GFP 
puncate formation, serial internal truncation were 
performed. Internal truncation of pro-EMAP II 
between amino acids 71 - 253 dramatically increased 
the amount of GFP punctate formation while 
truncation of pro-EMAP II between amino acids 71-
157, 71-203 and 71-94 did not significantly impact 
GFP punctate formation (Figure 5A, B). Further 
internal truncations between amino acids 204-253 
were performed to identify the region within the 
amino acid span of 204-253 that impacted the GFP 
punctate formation of pro-EMAP II. We determined 
that the internal truncation of 71-233aa resulted in a 
1.8 fold increase in GFP punctate formation (p<0.01), 
as compared 71-223aa truncation, indicating that the 
amino acid region between 203-233 of pro-EMAP II 
represses GFP punctate formation (Figure 5C, D). 
To further narrow the repressing region, fragments of 
C-terminus of pro-EMAP II were linked with 1-70aa 
region through a 15aa flexible peptide linker 
[(GGGGS)3] (Figure 5F) (36). Optimization of codon 
pair use within the (GGGGS)3 linker sequence is 
known to enhance protein expression. Transfection 
experiments containing C-terminus pro-EMAP II 
fragments 147-170aa, 181-210aa or 200-230aa 
resulted in a respective marked 3.2-, 4.5- or 7.0-fold 
decrease of GFP punctate formation as compared 
with 1-70aa alone, implying that multiple regions 
within the C-terminus have repressive effects on GFP 
punctate formation (Figure 5F). In addition to the 
amount of punctate protein formation, a change in 
morphology of GFP punctate was also observed in 
A549 cells transfected with full-length pro-EMAP II, 
while internal truncation at 71-203aa resulted in a 
dot-like GFP punctation (Figure 5E). However, 
internal deletion of the 71-212aa span induced a 
small strip-like change to the GFP punctate structure 
while further internal deletions of 71-223aa, 71-
233aa, 71-253aa resulted in strong and strip-like GFP 
punctate structure. Analysis of pro-EMAP II 
identified three potential coiled-coil structures, 1M-
80FI, 108G-148K, and and 199-219R with these 
sequences extending more than 35 residues 
suggesting a probability of >80-90% that they will 
assume a coiled-coil structure (Figure 3B). 
 
The 1-70aa region of pro-EMAP II binds with its C-
terminus. 
To examine if 1-70aa region of pro-EMAP II binds 
with itself, HEK293 cells were transfected with GFP 
control and 1-70aa fused with GFP. Cells were cross-
linked using DSS. Western blotting analysis 
determined that multiple bands of 35kD increment 
were observed in 1-70aa transfection treated with 
DSS, but not in GFP control and untreated cells 
(Figure 6A). This suggested that the 1-70aa region of 
pro-EMAP II fused with GFP might form a polymer 
structure within cells. Using his-tagged 1-70aa as bait 
and GST-tagged pro-EMAP II fragments 
recombinant protein as prey (Figure 6B), a his-tag 
pull-down assay was performed to determine binding 
between the N and C terminus regions of pro-EMAP 
II. As shown in Figure 6C, his-tagged 1-70aa 
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strongly pulled down GST-tagged 1-70aa and GST-
tagged C-terminus of pro-EMAP II (146-312aa), but 
not GST control, GST tagged 74-146aa or 1-70aa 
mutant. These experiments revealed the binding of 1-
70aa N-terminus region to the C-terminus of pro-
EMAP II. 
 
EMAP II’s N-terminus region 1-70aa is a binding 
partner of the MSC complex RARS but not QARS:  
Previous reports support the N-terminus region of 
pro-EMAP II as a component of the MSC where it 
has been identified as binding to itself as well as to 
p38, RARS, QARS and the leucine zipper of AIMP2. 
To establish the binding domain of two of the key 
MSC proteins, RARS and QARS, we examined their 
ability to bind to the pro-EMAP II N-terminus region 
extending from 1-70aa. Using his-tagged 1-70aa of 
pro-EMAP II as bait and recombinant GST-tagged 
RARS and QARS N-terminus as prey, we determined 
that pro-EMAP II pulled down GST-tagged RARS 
(1-102aa) but not GST control or GST-QARS (1-
108aa) (Figure 7A). Point-mutations of pro-EMAP II 
at I21->A, I37->A, L38->A, I21->A I22->A L25->A 
(Figure 7B and 7C) defined the RARS binding region 
to be dependent on the leucine at amino acid 42 and 
55 as pro-EMAP II mutant L42->A L55->A did not 
immunoprecipitate with RARS (Figure 7B, C). 
Furthermore, co-transfection of 1-70aa of pro-EMAP 
II fused with GFP or DsRed reporter resulted in two-
colored co-localized punctate structure (Figure 7E), 
whereas of GFP empty vector control and DsRed 
fused with 1-70aa did not co-localize (Figure 7D). 
Punctate RARS protein expression was dependent on 
the presence of EMAP II 1-70aa (Figure 7G) as 
overexpression of RARS (1-74aa) fused with GFP 
alone showed no punctate (Figure 7F).  
 
GFP Punctate pro-EMAP II 1-70aa are cytoplasmic. 
In order to better understand the role of the 1-70aa 
pro-EMAP II punctate formations, we examined its 
pattern of intracellular distribution in conjunction 
with known organelle markers. Live staining of 
transfected cells with nuclei stain Hoechst 33343 
indicated that 1-70aa GFP punctate was not nuclear 
(Figure 8A,B,C). Although, the addition of a nuclear 
localizing signal (NLS) fused to the 1-70aa and GFP 
partitioned the 1-70aa GFP fusion protein to the 
nucleus, no GFP punctate lesions were observed in 
nuclei (Figure 8D). On account of the cytoplasmic 
partitioning of the 1-70aa pro-EMAP II GFP punctate 
lesions, we examined whether the Golgi apparatus, 
lysosomes, aggresomes or endosomes markers co-
localized with these punctate lesions. Due to a 
significant lack of effective organelle antibodies, co-
transfection experiments were performed. Co-
transfection of 1-70aa GFP with the late endosome 
marker Rab7 fused with DsRed (Figure 8E across 
upper panels), with Golgi marker GalT (Figure 8F 
across middle panels) or lysosomal marker lamp1 
fused with YFP showed no punctate co-localization 
(Figure 8G across lower panels). These studies were 
validated by examination of purified punctate lesions 
and subsequent mass spectrometry analysis of 
binding partners isolated and bound to the punctate 
lesions. Cross-linking assays revealed no interaction 
between the GFP punctate pro-EMAP II 1-70aa 
formations and known organelle markers (data not 
shown). While treatment of cells with BFA to induce 
the disassembly of Golgi apparatus does not alter the 
1-70aa GFP punctate formation (Figure 8H-M), 
consistent with the above observation that 1-70aa 
GFP punctate does not co-localized with Golgi 
apparatus or the nuclei. Similarly, the 1-70aa GFP 
punctate did not co-localize with the aggresome 
markers Vimentin and Ubiquitin even in the presence 
of the proteasome inhibitor PS-341 (data not shown). 
Furthermore, treatment of cells transfected with the 
mutant L66->A that demonstrates reduced punctate 
formation using PS-341, did not increase GFP 
punctate formation (data not shown).  
 
Insoluble 1-70aa pro-EMAP II GFP punctate 
formation binds to NFL. 
To determine binding partners associated with the 1-
70aa GFP punctuated formation, GFP punctate 
lesions were isolated following transfection of 1-70aa 
pro-EMAP II into neuroblastoma SH-SY5Y cells. 
Our initial observations determined that these 
punctate formations were predominately insoluble as 
the 1-70aa GFP was detected in insoluble fraction 
while GFP control was detected only in supernatant 
by Western blot analysis (Figure 9A). This was 
further supported by microscopic fluorescent analysis 
that the 1-70aa GFP punctate formations were 
observed in cell debris after lysis in buffer containing 
1% Triton X-100 and intensive wash (Figure 9B). 
Following a brief sonication, 1-70aa GFP punctate 
was released from debris into supernatant, pelleted 
and underwent flow cytometry enrichment. Mass 
spectrometry analysis of the enriched 1-70aa GFP 
punctate formations and their binding partners 
determined that they bound NFL polypeptide with 11 
peptide spectrum matches. Immunoprecipitation from  
cells transiently transfected with 1-70aa GFP EMAP 
II N-terminus confirms binding of NFL with the pro-
EMAP II N-terminus (Figure 10E). As mass 
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spectrometry analysis and previous reports indicate 
co-localization of pro-EMAPII and the 
neurofilaments found in neurons and neuroblastoma 
cells SH-SY5Y, co-transfection with 1-70aa GFP and 
DsRed-NFL were undertaken. Human NFL subunit 
gene was cloned and fused with DsRed. Transfection 
of the DsRed-NFL in A549 cells and SH-SY5Y cells 
induced a punctate formation (Figure 10A-D). 
Furthermore, co-transfection of DsRed-NFL and with 
either the 1-70aa (Figure 10A,C) or full-length pro-
EMAP II fused (Figure 10B,D) with GFP resulted in 
co-localization and co-punctate lesions supporting an 
interaction between 1-70aa region of pro-EMAP II 
and NFL fibers (Figure 10A-D). C-terminus 146-
312aa EMAP II C-terminus does not 
immunoprecipitate with NFL (Figure 10E). 
 
DISCUSSION 
Pro-EMAP II is abundantly expressed in all cell types 
and is a component of the multi-enzyme assemblage 
of eleven polypeptides that form the essential link to 
the structural organization of the mammalian cells 
cytoplasmic translation apparatus, the MSC complex. 
Based on bioinformatical analysis, pro-EMAP II 
protein was predicted to have of an N-terminus and 
C-terminus (37). The N-terminus contains a coiled-
coil structure, which may play an important role in 
protein-protein interaction. Furthermore, the N-
terminus of pro-EMAP II has been reported to 
interact with its own N-terminus, p38, RARS, QARS 
and leucine zipper of AIMP2 (21,23,24,38) 
suggesting that the N-terminus may mediate the 
association of pro-EMAP II to MSC. However, the 
structure and function of N-terminus of pro-EMAP II 
remains obscure. Through GFP punctate analysis and 
pull-down assay, we showed that the truncation of 
pro-EMAP II to 1 to 70aa resulted in strong and 
specific strip like punctate structure that was 
mediated by the leucine-like residues within the 1-
70aa region of pro-EMAP II. In addition to the self-
binding of the 1-70aa region, we determined that it 
also binds the C-terminus of pro-EMAP II through a 
putative leucine zipper motif and is the region that is 
the binding partner of the MSC complex polypeptide 
RARS but not the QARS. We also determined that 
the punctate GFP pro-EMAP II 1-70aa aggregate co-
localizes and binds to the NFL subunit protein. These 
findings show that the 1-70aa region of the pro-
EMAP II N-terminus is responsible for the binding of 
MSC subunits and may be the region of the N-
terminus of pro-EMAP II that facilitates the 
interaction of the MSC complex with RNA-binding. 
 
Transcriptional regulation is dependent on the 
flexibility and interaction of the participating protein 
complexes. Leucine zippers play an important role in 
this process by mediating protein-protein interactions 
and transcriptional regulation where they serve as 
folding triggering sequences in coiled-coil structures 
(39) (40). Pro-EMAP II, a component of the MSC 
complex, functions as a cofactor of aminoacyl-tRNA 
synthetases whose involvement is as a general RNA 
binding domain (41). We hypothesized that pro-
EMAP II contained a putative leucine zipper that 
would allow it greater flexibility in the mediation of 
protein-protein interactions. Using mutation analysis, 
we showed that specific leucine or isoleucine 
residues are critical for GFP punctate formation, but 
abundant lysine residues have little effect. Our cross-
linking and pull-down assay results showed that the 
1-70aa region of pro-EMAP II interacts with itself, 
the C-terminus of pro-EMAP II and N-terminus 
RARS. Importantly, some leucine mutants abolished 
the binding with RARS suggesting the relevance of 
the leucine binding regions. Thus, our data provide 
detailed information to support that N-terminus of 
pro-EMAP II functions as a putative leucine zipper, 
which is consistent with previous prediction and 
other reports (38).  
 
In contrast to the GFP punctate lesions seen 
following overexpression of the 1-70aa pro-EMAP II, 
not all leucine-zipper-like domains of the MSC 
proteins have a similar expression pattern. For 
example, although RARS is one component of MSC 
and contains a leucine-zipper-like domain at the N-
terminus, overexpression of RARS leucine zipper 
domain showed no GFP punctate structure. This 
implies the specific characteristics of the putative 
leucine zipper of pro-EMAP II. The underlying 
mechanism of GFP punctate formation remains 
unclear. Cross-linking analysis and pull-down 
analysis suggest protein-protein interaction and 
protein polymerization may play some role in 
forming strip like structure. Co-transfection 
experiments suggest the punctate structure is not co-
localized with the markers of aggresome, Golgi 
apparatus, lysosome or endosome. BFA treatment 
experiments also suggest GFP punctate formation is 
not relevant to ER pathway.  Our data showed 1-70aa 
GFP colocalizes with NFL. This is consistent with 
the finding of colocalization and interaction of pro-
EMAP II with NFL (31), which implies GFP 
punctate formation may be related to neurofilament 
structures.  
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Internal interaction of proteins is critical for its 
proper and effective folding and maintenance of a 
proteins functional structure (42). Protein misfolding 
and aggregation may play an important role in the 
pathological process of disease processes such as 
neurodegenerative diseases. Fore example, in 
transfection experiments with full-length of pro-
EMAP II, only rare GFP punctate was observed 
compared with the transfection with the N-terminus 
1-70aa GFP. However, presence of the C-terminus of 
pro-EMAP II induced a repressive effect on GFP 
punctate formation. These findings suggested that the 
C-terminus of pro-EMAP II might fold back and bind 
with its N-terminus region to cover up the active 
moiety of putative leucine zipper. Through truncation 
of C-terminus, we were able to expose the putative 
leucine zipper resulting in the GFP punctate 
formation. On the other hand, folding up between N-
terminus and C-terminus may also prevent the 
exposure of an active C-terminus moiety. In our 
experiments to establish stable clones, we could 
easily obtain clones overexpressing 1-70aa GFP but it 
was difficult to obtain stable clones overexpressing 
C-terminus EMAP II fused with GFP (data not 
shown). Previous studies in our laboratory also 
showed that the overexpression of C-terminus of pro-
EMAP II inhibits cell proliferation (43). These data 
suggest that the N-terminus putative leucine zipper 
plays an important role in maintenance of proper 
soluble structure status and function of full-length 
pro-EMAP II, which are the results of natural 
selection during evolution.  
 
Although the mechanism of GFP punctate formation 
is complicated, it is the results of specific or 
nonspecific protein internal interaction or protein-
protein interactions. As we know, most native 
proteins are soluble in vivo. When proteins are 
truncated or mutated, spatial hindrance will be 
removed and aggregates and other specific punctate 
structures may form. As shown in our experiments, 
overexpression of pro-EMAP II resulted in small 
dotted like punctate structures in a few cells. Gradual 
truncation of C-terminus of pro-EMAP II not only 
increases the ratio of GFP punctate formation, but 
also resulted in strong and long strip like punctate 
structure, mimicking the process of gradual exposure 
of a putative leucine zipper of pro-EMAP II to 
environment following gradual removal of its C-
terminus. Our experiments suggest that GFP punctate 
analysis can be used as one of the powerful tool to 
dissect protein structural information. 
 
Feinstein M et al (33) found truncation of C-terminus 
of pro-EMAP II in consanguineous Israeli Bedouin 
kindred, who suffer from a severe axonal disease. 
Loss of C terminus may be the cause of the disease. 
To our notice, the 1-97aa of N-terminus of pro-
EMAP II remains intact in these patients with C-
terminus truncation. In brain, pro-EMAP II is highly 
expressed. In our experiments, truncation of C-
terminus resulted in strong strip like punctate 
formation. It is possible that such kind of punctate 
structure could be found in the neurons of these 
patients. Our data in SH-SY5Y human neuronal cells 
that have been widely studied as in vitro models of 
neuronal function, differentiation, (44-46) and in 
Parkinson’s disease (47-49), we show co-
localization of 1-70aa GFP with NFL. This is 
consistent with the report that pro-EMAP II co-
localizes and binds with neurofilament. Knock-out 
mice of pro-EMAP II show axon development defect 
in motor neurons (31). These findings suggest that 
pro-EMAP II may play an important role in axon 
assembly. It is well known that protein aggregation 
plays an important role in many neurodegenerative 
diseases such as Alzheimer disease. If punctate 
formation or exposure of the putative leucine zipper 
occurs within these disease process, one may 
consider their potential role in disease progression as 
our experiments show that even one amino acid 
mutation abolishes GFP punctate formation. This 
implies the possibilities to alter protein structure 
through targeting the key amino acid residues leading 
to prevention and treatment of neurodegenerative 
diseases. 
 
In conclusion, we have established an approach to 
study the structure and function of pro-EMAP II 
using GFP punctate analysis and pull-down assay. 
Utilizing this technique, we determined that the N-
terminus of pro-EMAP II can bind with its C-
terminus to repress punctate structure formation, has 
a putative leucine zipper, is the region responsible for 
the binding of MSC subunits, and co-localizes to the 
NFL subunit protein These findings indicate the 
structure and binding interaction of pro-EMAP II 
protein and suggest a role of this protein in the 
pathological neurodegenerative diseases.
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FIGURE LEGENDS: 
 
FIGURE 1: Regulation of GFP punctate structure formation EMAP II aggregation by the 1-70aa N-
terminus region of pro-EMAP II in A549 cells. Compared to empty vector alone, transfection of full-length pro-
EMAP II (1-312aa) (B) fused to a GFP expression vector demonstrated a <1% of dotted-like GFP punctate 
structures as compared to empty vector alone (A). Analysis of GFP punctate formation in multiple truncated forms 
of pro-EMAP II (B-I, arrows) was performed in live cells. Calculation of percentage of GFP punctuated cells 
revealed that the presence of the 1-70aa region (D- arrows, J) was critical for this formation (J) as most constructs 
resulted in minimal to no punctate formation (J, construct aligned with graph representing percentage of GFP 
punctate cells found in transfected GFP positive cells with each construct). Morphologic variation of GFP punctate 
structures with strip-like regions of variable lengths (arrows) were identified in cells transfected with 1-70aa 
truncation (L-S) as compared to the consistent perinuclear punctate lesions seen in the full-length pro-EMAP II 
transfected cells (K, arrow). Representative image shown and analysis were performed on an n=100-200 
cells/experiment and each experiment were repeated 3-6 times on different occasions. Magnification: A-I: 100x K-
S: 200X 
 
FIGURE 2: HEK293 and SH-SY5Y neuroblastoma cells exhibit GFP aggregates when transfected with 1-
70aa N-terminus region of pro-EMAP II. Following transfection with 1-70aa pro-EMAP II, GFP punctation was 
visualized in HEK293 cells and SH-SY5Y cells (G, arrows C and F), respectively) as compared to empty vector 
alone (A, D), or the C-terminusterminus pro-EMAP II (no punctate lesions seen, data not shown) in living cells. 
Representative image shown and analysis were performed on an n=100-200 cells/experiment and each experiment 
was repeated 3-6 times on different occasions.  Magnification: 200X. (B) Calculation of percentage of GFP 
punctated cells in SH-SY5Y cells. 
 
FIGURE 3: Region 1-70aa of pro-EMAP II (AIMP1) is highly conserved across species and is predicted to 
have a Coiled-coil Structure. Evaluation of the N-terminus of pro-EMAP II determined that the region is highly 
conserved in evolution (A). Using the Lupas Software, three potential coiled-coil structure in pro-EMAP II protein 
were identified, 1M-80FI, 108G-148K, and 199L-219R with these sequences extending more than 35 residues 
suggesting a probability of >80-90% that they will assume a coiled –coil structure (B). 
 
 
FIGURE 4: Leucine-like residues in the 1-70aa region of pro-EMAP II have a role in GFP-punctate 
formation. Stripe replacement of lysine residues with alanine residues  (lysine mut in C and 8-11aa mut in D) had 
no impact on GFP punctate lesions in A549 cells transfected with these constructs as compared to wild type 1-70aa 
GFP (B) control. In contrast, replacement of the hydrophobic leucine or isoleucine residues with alanine resides at 
I21 →A (E), L25→A (G), L31→A (H), L32→A (I), I37→A (J), L38→A (K,Q), L42→A (L), L55→A (M,Q), 
I59→A (N), and  L62→A (O) abolished GFP punctate formation. While exchange of a leucine for an alanine at 
L66→A reduced GFP punctate formation (P,Q). Site-directed mutagenesis of I22→A showed no significant 
difference in GFP punctation (F). Magnification: 100X.  
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FIGURE 5: C-terminus region of pro-EMAP II suppresses the GFP punctate formation and alters GFP 
punctate morphology. A549 cells transfected with constructs of serial internal truncations between amino acids 
71-253 of pro-EMAP II markedly increased GFP punctate formation (A, B). Additional internal truncations 
between 204-253 increased GFP punctate formation (C, D) with the elimination of the 71-233 having a significant 
impact over 71-203 suggesting the 203-233 aa region of pro-EMAP II represses GFP punctate formation (C,D). 
Decreases in GFP punctate formation in the truncated forms of pro-EMAP II was associated with marked 
morphologic changes where internal deletion of the 71-212aa span induced a small strip-like change, while further 
internal deletions of 71-223aa, 71-233aa, 71-253aa resulted in strong and strip-like GFP punctate structure (E). 
Using a flexible linker, transfection with c-terminus pro-EMAP II fragments 147-170aa, 181-210aa or 200-230aa 
decreased GFP punctate formation by 3.2, 4.5, and 7 fold as compared to 1-70aa alone (F). Magnification: 100X- 
A,C, 200X- E. 
 
FIGURE 6: N-terminus region of pro-EMAP II binds with its C-terminus. (A) Cross-linking of HEK293 cells 
transfected with 1-70aa fused with GFP resulted in multiple bands at 35kD increments in Western blot analysis as 
compared to non-crosslinked and empty GFP vector controls. (B) Multiple fragments of GST-tagged pro-EMAP II 
recombinant protein were designed and used as prey, with  his-tagged 1-70aa pro-EMAP II recombinant protein as 
bait. Following isolation, GST tagged 1-70aa and 146-312aa pro-EMAP II were found to bind strongly to his-
tagged 1-70aa pro-EMAP II, but not with GST control, GST tagged 74-146aa or 1-70aa mutant (B). (C) Input 
recombinant pro-EMAP II protein isolates are shown by Comassie Blue stain.  
 
FIGURE 7: Pro-EMAP II N-terminus region 1-70aa is a binding partner of the MSC complex RARS.  (A) 
Recombinant His tagged 1-70aa pro-EMAP II protein pulled down GST-RARS but not GST-QARS or GST alone. 
(B) Using His-RARS as bait, point mutations of pro-EMAP II determined that the RARs binding was dependent on 
the leucine at amino acid position 42 as mutation of this aa (L42->A) inhibited pull down of GST-L42->A 1-70aa 
pro-EMAP II. Recombinant input shown below. (C) Similarly, mutation of the leucine at amino acid position 55 
(L55->A) of 1-70aa pro-EMAP II inhibited its pull down with RARS. Recombinant input shown below. Co-
transfection of pro-EMAP II 1-70aa-GFP with DsRed-1-70aa pro-EMAP II resulted in co-localization of the 
intracellular punctate regions (E). Similarly, RARS (1-74aa)-GFP forms co-localized punctate intracellular regions 
when co-transfected with DsRed-1-70aa pro-EMAP II (G). In contrast, transfection with RARS(1-74aa)-GFP alone 
had no punctate lesions (F) and GFP empty vector with DsRed -1-70aa pro-EMAP II resulted only DsRed-1-70aa 
pro-EMAP II punctation without co-localization (D). Magnification: 100X (D-G). 
 
FIGURE 8: The N-terminus 1-70aa pro-EMAP II punctate lesions are cytoplasmic. The GFP punctate lesions 
in A549 cells transfected with 1-70aa GFP pro-EMAP II did not co-localize with DAPI staining and were noted to 
be cytoplasmic (A,B,C). Addition of a nuclear localizing sequence (NLS) to the 1-70aa GFP pro-EMAP II 
construct resulted in nuclear localization but lacked punctate formation in nuclei (D). 1-70aa GFP pro-EMAP II 
cytoplasmic punctate lesions were not associated with the endosome marker Rab7 (E), Golgi marker GalT (F), or 
the lysosomal marker lamp1 (G). BFA treatment disassembled the Golgi apparatus (K,M) as compared to untreated 
control (J,L), but didn’t alter 1-70aa GFP pro-EMAP II punctate formation (H,I,L,M) or promote interaction 
between these formations and the disassembled Golgi (M). Magnification: 100X E-G, 200X C,D, 400X A,B,H-M. 
 
FIGURE 9: Isolation of insoluble 1-70aa pro-EMAP IIGFP punctate formation using flow cytometry 
enrichment.  GFP punctate lesions were isolated from neuroblastoma SH-SY5Y cells transfected with 1-70aa pro-
EMAP II. (A) Western analysis of the supernatant and pellet determined that the 1-70aa GFP was predominately 
found in the insoluble fraction (pellet) in contrast to the GFP vector control that was found only in the supernatant. 
(B) Systematic lysis with 1% triton X-100, sonication, pelleting and flow cytometry enrichment of the GFP 
punctate formations was performed and evaluated by light microscopy. Magnification: 100X  
 
FIGURE 10: Punctate formations of 1-70aa and 1-312aa GFP pro-EMAP II co-localize and 
immunoprecipitates with NFL. Cells were co-transfected with either 1-70aa or 1-312aa GFP pro-EMAP II and 
DsRed- human NFL gene. Co-localization and co-punctate lesions were identified in cells co-transfected with 
DsRed-NFL and either the 1-70aa GFP (A,B) and 1-312aa GFP pro-EMAP II (B,D). Cell lysate from using 
transient transfected with 1-70aa GFP EMAP II, 1-312aa GFP pro-EMAP II, 146-312aa GFP EMAP II, or empty 
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vector were immunoprecipitated with GFP antibody. Western blot analysis using an NFL antibody confirms 
binding of the NFL with the EMAP II N-terminus domain and pro-EMAP II, but not the C-terminus (E) (IP with 
empty vector and control cell lysate was negative, data not shown). Magnification: 100X 
 
 
 at Indiana U
niversity School of M
edicine on July 1, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Figure 1 
J 
A 
D 
C B 
G 
F E 
H I 
K 
L 
P Q R 
M N 
S 
O 
 at Indiana U
niversity School of M
edicine on July 1, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
010
20
30
40
50
60
70
80
GFP 1-312aa 1-70aa
P
e
rc
e
n
ta
g
e
 o
f 
G
F
P
 P
u
n
c
ta
te
 C
e
ll
s
G 
Figure 2 
H 
D 
A B 
F E D 
C 
HEK293 
SH-SY5Y 
 at Indiana U
niversity School of M
edicine on July 1, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Figure 3 
B 
A 
 at Indiana U
niversity School of M
edicine on July 1, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Figure 4 
Q 
A 
E 
B 
F H G 
C D 
I J L K 
M N O P 
0 
10 
20 
30 
40 
50 
60 
70 
80 
Pe
rc
en
ta
ge
 o
f G
FP
 P
un
ct
at
e 
C
el
ls
 
 at Indiana U
niversity School of M
edicine on July 1, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
A 
C 
E 
B 
D 
F 
Figure 5 
 at Indiana U
niversity School of M
edicine on July 1, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
1mM DSS       -       +      -    +  
1-70aa-GFP      GFP 
A 
B 
Figure 6 
C 
 at Indiana U
niversity School of M
edicine on July 1, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
C 
A 
B
Figure 7 
GREEN RED MERGE 
RARS (1- 
74aa)-GFP 
DsRed-1-70aa 
RARS (1- 
74aa)-GFP 
1-70aa-GFP 
DsRed-1-70aa 
GFP 
DsRed-1-70aa 
D 
E 
F 
G 
 at Indiana U
niversity School of M
edicine on July 1, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Figure 8 
1-70aa-GFP 1-70aa-NLS-GFP 
C D 
GREEN RED MERGE 
1-70aa-GFP 
EYFP-GaIT 
LAMP1-YFP 
E 
F 
G 
1-70aa-GFP 
Control 
GM130 
MERGE 
10µg/ml 
BFA 4h 
H 
L M 
J K 
I 
A B 
 at Indiana U
niversity School of M
edicine on July 1, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Figure 9 
1-70aa-GFP 
Transfected 
Cells 
FAOS 
Purified 
Pellet 
Sonication 
1% Triton 
X-100 
FITC Light Microscopy 
A 
B 
 at Indiana U
niversity School of M
edicine on July 1, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Figure 10 
A
54
9 
SH
-S
Y5
Y 
A 
B 
C 
D 
E 
WB: NFL!
WB: GFP!
IP:GFP!
WB: NFL!
dsRED-NFL     
146-312aa GFP
 1-312aa GFP    
1-70aa GFP      
+  +  + 
-   -   + 
-   +   - 
+   -   - 
NFL 
25kD 
75kD 
37kD 
50kD 
 at Indiana U
niversity School of M
edicine on July 1, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
A. Schwarz
Awasthi, Roderich E. Schwarz and Margaret 
Haiming Xu, Nikolay L. Malinin, Niranjan
  
Synthetase, and Neurofilament light protein
binding with C-terminus, Arginyl-tRNA 
N-terminus of pro-EMAP II regulates its
Cell Biology:
 published online February 27, 2015J. Biol. Chem. 
  
 10.1074/jbc.M114.630533Access the most updated version of this article at doi: 
  
.JBC Affinity SitesFind articles, minireviews, Reflections and Classics on similar topics on the 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/early/2015/02/27/jbc.M114.630533.full.html#ref-list-1
This article cites 0 references, 0 of which can be accessed free at
 at Indiana U
niversity School of M
edicine on July 1, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
